Anticancer agent 69 

Anticancer agent 69 (Compound 34), a potent and selective anticancer agent , potently and selectively inhibits human prostate cancer cell line PC3 (IC₅₀=26 nM). Anticancer agent 69 increases ROS level, down-regulates EGFR and induces apoptosis^[1].

Anticancer agent 69 (Compound 34, 0-20 μM approximately, 72 h) has selective anticancer activity in PC3 cells with an IC₅₀ value of 26 nM against other cancer cell lines and normal cell lines^[1].
Anticancer agent 69 (1-7 days) inhibits the cell viabilities of PC3 cells and PC9 cells in a time- and dose-dependent manne^[1].
Anticancer agent 69 (0-100 nM, 7 days) forms fewer and smaller colonies compared those with DMSO-treated cells^[1].
Anticancer agent 69 (0-800 nM, 34/72 h) increases ROS production, and further stimulates Prx I-III expression, phosphorylation level of MAPK ‘s downstream proteins, expression of apoptosis-related proteins^[1].
Anticancer agent 69 (0-500 nM, 72 h) decreases the level of EGFR and phosphorylation level of its downstream protein (ERK, AKT), and induces PC3 cells and PC9 cells apoptosis in a dose-dependent manner^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

398.53

C₁₉H₂₆N₈S

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Chenhao Xu, et al. Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives containing hydrazone fragment as potent and selective anticancer agents. Bioorg Chem. 2020 Dec;105:104424.  [Content Brief]